eFFECTOR Therapeutics’ $7.5 Million Registered Direct Offering

Marco Zingaro
Tagged:

Latham & Watkins advises eFFECTOR Therapeutics in US$7.5 million registered direct offering.eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Marco Zingaro

…

This content is for Standard 1 Year members only.
Login Join Now